The Federal Circuit’s refusal to reconsider its ruling forcing Teva to delist asthma-inhaler patents from the FDA’s Orange ...

Management to Hold Investor Day Conference Call Today at 10:00am ETReported record product revenue of $11.6 million in Q4 2024, an increase of ...

Teva Pharmaceuticals filed a patent infringement lawsuit against Amneal Pharmaceuticals alleging that their generic version of ...

The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto, which brought in ...

Late last year we reported on the United States Court of Appeals for the Federal Circuit decision holding that certain device patents should not ...

Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for ...

In a volatile fourth quarter, the Wasatch Ultra Growth Fund—Investor Class returned 0.94% and slightly underperformed the benchmark Russell 2000® Growth Index, which rose 1.70%.

The Trump administration’s gutting of the U.S. Agency for International Development ended up halting efforts to clean up ...

VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 ...

Paxton’s office charged Rojas, known locally as “Dr. Maria,” with operating a network of clinics between Waller, Cypress, and Spring in the northwest Houston area. The clinics allegedly “unlawfully ...

IPA also stated that while generics are priced lower than the corresponding brands, it is unfair and unacceptable to link quality with cost.

A much-anticipated meeting between President Donald Trump and representatives of the pharmaceutical industry took place ...